Department of Medicine, Mount Sinai School of Medicine, New York, New York, United States of America.
PLoS One. 2013;8(1):e55145. doi: 10.1371/journal.pone.0055145. Epub 2013 Jan 25.
Breast cancer cell lines are widely used tools to investigate breast cancer biology and to develop new therapies. Breast cancer tissue contains molecularly heterogeneous cell populations. Thus, it is important to understand which cell lines best represent the primary tumor and have similarly diverse phenotype. Here, we describe the development of five breast cancer cell lines from a single patient's breast cancer tissue. We characterize the molecular profiles, tumorigenicity and metastatic ability in vivo of all five cell lines and compare their responsiveness to 4-hydroxytamoxifen (4-OHT) treatment.
Five breast cancer cell lines were derived from a single patient's primary breast cancer tissue. Expression of different antigens including HER2, estrogen receptor (ER), CK8/18, CD44 and CD24 was determined by flow cytometry, western blotting and immunohistochemistry (IHC). In addition, a Fluorescent In Situ Hybridization (FISH) assay for HER2 gene amplification and p53 genotyping was performed on all cell lines. A xenograft model in nude mice was utilized to assess the tumorigenic and metastatic abilities of the breast cancer cells.
We have isolated, cloned and established five new breast cancer cell lines with different tumorigenicity and metastatic abilities from a single primary breast cancer. Although all the cell lines expressed low levels of ER, their growth was estrogen-independent and all had high-levels of expression of mutated non-functional p53. The HER2 gene was rearranged in all cell lines. Low doses of 4-OHT induced proliferation of these breast cancer cell lines.
All five breast cancer cell lines have different antigenic expression profiles, tumorigenicity and organ specific metastatic abilities although they derive from a single tumor. None of the studied markers correlated with tumorigenic potential. These new cell lines could serve as a model for detailed genomic and proteomic analyses to identify mechanisms of organ-specific metastasis of breast cancer.
乳腺癌细胞系被广泛用于研究乳腺癌生物学和开发新疗法。乳腺癌组织包含分子异质性的细胞群体。因此,了解哪些细胞系最能代表原发性肿瘤,并且具有相似的表型多样性非常重要。在这里,我们描述了从单个患者的乳腺癌组织中开发的五个乳腺癌细胞系。我们对所有五个细胞系的分子谱、体内致瘤性和转移能力进行了表征,并比较了它们对 4-羟基他莫昔芬(4-OHT)治疗的反应。
从单个患者的原发性乳腺癌组织中分离出五个乳腺癌细胞系。通过流式细胞术、Western blot 和免疫组织化学(IHC)测定不同抗原(包括 HER2、雌激素受体(ER)、CK8/18、CD44 和 CD24)的表达。此外,对所有细胞系进行了 HER2 基因扩增和 p53 基因分型的荧光原位杂交(FISH)检测。利用裸鼠异种移植模型评估乳腺癌细胞的致瘤性和转移能力。
我们从单个原发性乳腺癌中分离、克隆并建立了五个具有不同致瘤性和转移能力的新乳腺癌细胞系。尽管所有细胞系均表达低水平的 ER,但它们的生长是雌激素非依赖性的,并且均高水平表达突变的无功能 p53。所有细胞系的 HER2 基因均发生重排。低剂量的 4-OHT 诱导这些乳腺癌细胞系的增殖。
尽管这五个乳腺癌细胞系均源自单个肿瘤,但它们具有不同的抗原表达谱、致瘤性和器官特异性转移能力。研究的标志物均与致瘤潜能无关。这些新的细胞系可以作为详细的基因组和蛋白质组学分析的模型,以确定乳腺癌器官特异性转移的机制。